Merck Sharp & Dohme Llc

This study tests a new dengue vaccine called V181 in 12,000 healthy children aged 2 to 17. The goal is to see if the vaccine is safe, triggers a good immune response, and lowers the number of dengue cases caused by any of the four dengue virus types. Participants will receive eit…

This early-stage study tests a new vaccine (V118C) to prevent pneumococcal infections in children. About 210 toddlers and infants will receive the vaccine to check its safety and how well the body responds. The goal is to see if this vaccine can protect against serious infections…

This study tests a new vaccine called V118E that aims to prevent diseases caused by Streptococcus pneumoniae bacteria, such as pneumonia. Researchers want to see if the vaccine is safe and well-tolerated in 126 healthy adults. Participants will receive either the new vaccine or a…

This early-stage study is testing two experimental vaccines (V350A and V350B) designed to prevent diseases caused by the Epstein-Barr virus, such as mononucleosis and certain cancers. About 250 healthy adults and teens will receive either the vaccine or a placebo to check for sid…

This study tests pembrolizumab, an immunotherapy that helps the immune system fight cancer, in children aged 6 months to 18 years with advanced melanoma, solid tumors, or lymphoma that has spread, returned, or not responded to treatment. The goal is to see if the drug can shrink …

This study tests the drug pembrolizumab in Japanese children with solid tumors or lymphomas, and in Japanese adults with advanced Merkel cell skin cancer. The main goals are to check the drug's safety, how the body processes it, and whether tumors shrink. About 20 participants wi…

This study tests whether a personalized cancer vaccine (intismeran) alone or combined with an immunotherapy (pembrolizumab) can prevent non-small cell lung cancer from returning after surgery. About 876 adults with high-risk stage I lung cancer that was fully removed will be rand…

This study tests whether combining the immunotherapy drug pembrolizumab with other treatments can help men with a hard-to-treat form of prostate cancer that has spread and stopped responding to hormone therapy. About 1,200 participants will receive different drug combinations acr…

This study tests two experimental drugs—MK-6070 and ifinatamab deruxtecan—alone or together, in people with advanced small cell lung cancer that came back or didn't respond to prior therapy. About 262 adults will join to see if these treatments shrink tumors and are safe. The goa…

This study tests whether adding new investigational drugs to the standard two-drug treatment (enfortumab vedotin plus pembrolizumab) can shrink tumors more safely in people with advanced bladder cancer that has spread. About 55 adults who have not had prior treatment for their ad…

This study tests two new treatments for people with advanced triple-negative breast cancer that has spread and has low PD-L1 levels. One group gets a new drug called sacituzumab tirumotecan alone, another gets it combined with pembrolizumab, and a third gets standard chemotherapy…

This study is for people with a type of kidney cancer (clear cell renal cell carcinoma) that has come back during or within 2 years after finishing a certain kind of immunotherapy (anti-PD-[L]1). The goal is to test if combining different experimental drugs is safe and can shrink…

This study tests a new targeted therapy, sacituzumab tirumotecan (Sac-TMT), as maintenance treatment for people with advanced ovarian cancer that is not HRD positive. After initial chemotherapy, participants will receive Sac-TMT with or without bevacizumab, or standard care. The …

This study tests a new medicine called tulisokibart for people with rheumatoid arthritis who are already taking methotrexate. The goal is to see if tulisokibart can reduce joint pain and swelling better than a placebo. About 182 adults with active arthritis will receive different…

This study tests whether adding belzutifan to fulvestrant works better than standard treatments for people with a common type of advanced breast cancer (ER+/HER2-) that has worsened after hormone therapy. About 120 adults will receive either the new combination or a standard drug…

This study tests whether adding an experimental drug (V940) to the standard immunotherapy (pembrolizumab) after surgery can help prevent non-small cell lung cancer from returning. It includes 680 adults whose tumors did not fully disappear with pre-surgery treatment. Participants…

This study tests a new medicine called MK-3120 for people with high-risk bladder cancer that hasn't spread to the muscle. After standard surgery to remove the tumor, participants receive MK-3120 directly into the bladder. The main goals are to check safety and side effects, and t…

This phase 3 study tests whether adding the experimental drug MK-2870 to the standard immunotherapy pembrolizumab helps people with advanced non-small cell lung cancer live longer compared to pembrolizumab alone. About 614 participants whose tumors have high PD-L1 levels will be …

This study tests an experimental drug called MK-8690 for people with moderate to severe ulcerative colitis, a condition causing gut inflammation. About 100 adults will receive either the drug or a placebo to see if it helps achieve remission (fewer symptoms and healed gut lining)…

This study is for people with advanced esophageal cancer that has gotten worse after standard treatments. It tests new drug combinations, with or without the immunotherapy pembrolizumab and chemotherapy, to see if they can shrink tumors or slow the cancer's growth. About 230 adul…

This study tests new drug combinations, including an antibody-drug conjugate, with the immunotherapy pembrolizumab (with or without chemotherapy) for people with advanced esophageal cancer that cannot be surgically removed or has spread. About 298 participants will join this earl…

This study tests whether adding a personalized cancer vaccine (V940) to standard immunotherapy (pembrolizumab) and chemotherapy helps people with advanced squamous non-small cell lung cancer live longer and keep their cancer from growing. About 180 participants will receive eithe…

This study tests a new drug called patritumab deruxtecan (HER3-DXd) in children whose liver cancer (hepatoblastoma) or muscle cancer (rhabdomyosarcoma) has come back or not responded to treatment. The drug is designed to attach to a protein on cancer cells and deliver a powerful …

This study tests whether adding the experimental drug MK-1084 to the standard immunotherapy pembrolizumab helps people with a specific genetic subtype of advanced lung cancer (KRAS G12C mutation) live longer without their cancer growing. About 600 adults with newly diagnosed, adv…

This study tests whether adding the experimental drug zilovertamab vedotin to standard chemotherapy (R-CHP) helps people with untreated diffuse large B-cell lymphoma live longer without their cancer growing or spreading, compared to the current standard treatment (R-CHOP). About …

This study tests a new drug called zilovertamab vedotin in children and young adults (up to age 30) whose blood cancers or solid tumors have come back or not responded to treatment. The goal is to see if the drug is safe and can shrink or control the cancer. About 90 participants…

This study tests a new medicine called ifinatamab deruxtecan (I-DXd) against standard chemotherapy (docetaxel) in people with metastatic castration-resistant prostate cancer (mCRPC), a type of prostate cancer that has spread and no longer responds to hormone therapy. About 1,440 …

This study tests a new drug, MK-2870, against standard chemotherapy for people with a specific type of advanced lung cancer (EGFR-mutated non-squamous non-small cell lung cancer) that has worsened despite prior targeted therapy. About 520 participants will be randomly assigned to…

This study tests whether adding a new drug (MK-2870) to standard immunotherapy (pembrolizumab) can prevent breast cancer from returning in people with triple-negative breast cancer who still had cancer after initial treatment and surgery. About 1,530 participants will receive eit…

This study tests whether adding a targeted drug (MK-1084) to standard immunotherapy after surgery can prevent lung cancer from returning in people with a specific KRAS gene mutation. About 400 adults with stage IIA-IIIB non-small cell lung cancer that has been fully removed will …

This study tests whether adding the experimental drug V940 to standard BCG immunotherapy helps people with high-risk non-muscle invasive bladder cancer live longer without their cancer returning or spreading. About 308 adults whose bladder cancer has not invaded the muscle will b…

This study tests whether adding sacituzumab tirumotecan (Sac-TMT) to standard pembrolizumab helps people with advanced or recurrent endometrial cancer live longer without the cancer growing. About 1,100 participants with a specific type of cancer (pMMR) will receive either the co…

This study tests a drug called patritumab deruxtecan in people with advanced gastrointestinal cancers that have spread. The main goals are to see if the drug is safe and how many people's tumors shrink or disappear. About 180 adults with certain types of stomach, bowel, liver, or…

This study tests a new drug called bomedemstat against the standard treatment hydroxyurea in people with essential thrombocythemia (ET) who have not yet received treatment to lower their blood cell counts. The goal is to see if bomedemstat is better at safely reducing platelet co…

This study tests whether adding an experimental mRNA vaccine (V940) to standard immunotherapy (pembrolizumab) can better prevent lung cancer from returning after surgery. About 868 people with stage II to IIIB non-small cell lung cancer who have had their tumor completely removed…

This study tests whether a new drug, nemtabrutinib, combined with venetoclax works better than the standard venetoclax plus rituximab for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or stopped responding to treatment. Abou…

This study tests a new drug called MK-5684 (opevesostat) against two standard drugs (abiraterone or enzalutamide) in men with a type of advanced prostate cancer that has spread and stopped responding to hormone therapy and chemotherapy. About 1,310 men will be randomly assigned t…

This study tests a new medicine called tulisokibart for people with radiographic axial spondyloarthritis, a type of arthritis that causes pain and stiffness in the spine and hips. Researchers want to see if different doses can improve symptoms better than a placebo. About 315 adu…

This phase 3 trial tests whether adding the targeted drug sacituzumab tirumotecan to standard immunotherapy (pembrolizumab) and a blood-vessel blocker (bevacizumab) helps people with metastatic cervical cancer live longer or keep their cancer from growing. About 1,000 participant…

This early-phase study tests a new drug called MK-4716, given alone or with other treatments, for people with advanced solid tumors that have a specific KRAS gene change. The main goal is to check the drug's safety and how well people tolerate it. About 250 participants will take…

This study tests a new drug, patritumab deruxtecan, against standard chemotherapy or another drug for people with a common type of advanced breast cancer (HR+/HER2-). The goal is to see if the new drug helps people live longer or keeps the cancer from growing. About 1000 particip…

This study tests a new drug called MK-1084, alone or combined with cetuximab, for people with advanced solid tumors that have a specific gene change (KRAS G12C). About 150 adults whose cancer has worsened after standard treatments will receive the drug to see if tumors shrink or …

This study tests different drug combinations, including the immunotherapy pembrolizumab, in people with advanced non-small cell lung cancer. It uses an "umbrella" design, meaning participants are grouped based on their tumor type and genetics. The goal is to find which treatments…

This early-phase study tests an experimental drug called MK-0472, given alone or with other cancer drugs (pembrolizumab or MK-1084), in people with advanced solid tumors that have spread. The main goals are to check safety, find the right dose, and see if the drug helps control t…

This study tests an experimental drug called MK-5684 (opevesostat), alone or with other treatments, for men with a type of advanced prostate cancer that no longer responds to standard hormone therapy. About 220 participants will join to see if the drug is safe and can shrink tumo…

This study tests a new drug, MK-2870, against standard treatments for people with cervical cancer that has come back or spread. About 686 participants whose cancer worsened after initial therapy will receive either MK-2870 or a doctor-chosen treatment. The main goal is to see if …

This study tests a new pill, MK-1084, for people with advanced non-small cell lung cancer that has a specific gene change called KRAS G12C. The drug targets this change to try to shrink or stop the cancer. About 130 participants will receive the drug, and researchers will check f…

This study tests a new drug called bomedemstat against the best available treatments for people with essential thrombocythemia, a blood disorder causing too many platelets. It is for those who did not respond well to or could not tolerate the standard drug hydroxyurea. About 340 …

This study tests two new medicines, gocatamig and I-DXd, alone or with standard treatment, for people with extensive-stage small cell lung cancer (cancer that has spread). The goal is to see if the combination is safe and helps shrink or control the cancer. About 170 adults will …

This study is testing a new drug called patritumab deruxtecan in people with a type of advanced breast cancer (HER2-positive) that cannot be removed by surgery or has spread to other parts of the body. The main goals are to check the drug's safety and see if it can shrink or stop…

This study tests an experimental drug called MK-2214 in 340 people with early Alzheimer's disease. The goal is to see if it can slow the buildup of a harmful protein called tau in the brain, which damages brain cells. Participants will receive either the drug or a placebo, and re…

This study compares the immunotherapy drug pembrolizumab with standard chemotherapy in 100 Chinese patients whose advanced colorectal cancer has specific genetic markers (MSI-H or dMMR). The goal is to see if pembrolizumab can better delay cancer growth or improve survival. Parti…

This study tests a new drug called ifinatamab deruxtecan, given alone or with other treatments, in people whose prostate cancer has spread and stopped responding to hormone therapy. The goal is to find safe doses and see if the drug can shrink tumors or lower PSA levels. About 36…

This study tests a new drug called MK-2870, alone or with other cancer treatments, for people with advanced colorectal, pancreatic, or bile duct cancers that have spread or cannot be removed by surgery. The main goals are to check the drug's safety and see how many patients' tumo…

This study tests a drug called belzutifan in people with advanced cancers linked to a protein called HIF-2α, including rare tumors like pheochromocytoma/paraganglioma and VHL disease. The goal is to see if the drug can shrink tumors or stop them from growing. About 322 participan…

This study tests whether adding the drug MK-2870 to standard pembrolizumab after initial chemo-immunotherapy helps people with advanced squamous non-small cell lung cancer live longer. About 851 participants will receive pembrolizumab plus chemotherapy, then either continue pembr…

This study tests a new medicine called MK-1084 in people with advanced non-squamous non-small cell lung cancer that has a specific genetic change (KRAS G12C). The goal is to see if the drug is safe and can shrink tumors. About 190 adults who have already tried other treatments wi…

This study tests whether a once-weekly combination pill (islatravir and ulonivirine) works as well as a standard daily HIV medication (Biktarvy) in adults who have never taken HIV treatment before. About 570 participants will be randomly assigned to either the weekly pill or the …

This study tests an oral drug called MK-1026 (nemtabrutinib) in about 490 people with certain blood cancers, including chronic lymphocytic leukemia, non-Hodgkin lymphoma, and Waldenström's macroglobulinemia. The main goals are to check safety and see how well the drug shrinks or …

This study tests whether a new drug combination (sacituzumab tirumotecan with or without bevacizumab) can help people with platinum-sensitive recurrent ovarian cancer live longer without their cancer worsening. About 770 adults who have already had two rounds of chemotherapy will…

This study looks at the long-term safety of the drug sotatercept for people with a specific type of high blood pressure in the lungs caused by heart failure. About 130 adults who completed a previous sotatercept study can join. Researchers will monitor side effects and how well p…

This study tests a drug called vericiguat in children with heart failure caused by a weak left heart pump. About 342 kids aged 1 month to 18 years will receive either vericiguat or a placebo for 16 weeks to see if it improves heart function. The goal is to find a better treatment…

This study tests whether adding the targeted drugs MK-1084 and cetuximab to standard chemotherapy (mFOLFOX6) helps people with a specific genetic mutation (KRAS G12C) in advanced colorectal cancer live longer without the cancer growing. About 477 participants will be randomly ass…

This study tests whether adding new drugs to standard chemotherapy and pembrolizumab before surgery can completely eliminate cancer cells in people with stage II to IIIB non-small cell lung cancer. About 60 participants will receive the combination, then have their tumors and lym…

This study tests whether a combination of two drugs (belzutifan and zanzalintinib) works better than the standard drug cabozantinib for people with advanced kidney cancer that came back after previous treatment. About 904 participants will be randomly assigned to one of the two t…

This study tests two new drug combinations for people with advanced stomach, gastroesophageal junction, or esophageal cancer that has gotten worse after one prior treatment. About 210 participants will receive either an experimental antibody-drug combo plus standard chemo, or sta…

This study is testing a medicine called posaconazole in infants under 2 years old who have serious fungal infections. The goal is to find the right dose and make sure it is safe for this age group. About 40 babies will take part, receiving the medicine through an IV or as a liqui…

This study looks at the long-term safety of tulisokibart, a medicine for moderate to severe Crohn's disease and ulcerative colitis. People who already took tulisokibart in an earlier study can join. Researchers will track side effects and how well people tolerate the drug over ti…

This study tests a new medicine called enlicitide decanoate in children and teens with a genetic condition that causes very high cholesterol (heterozygous familial hypercholesterolemia). The goal is to see if the drug is safe, tolerable, and lowers bad cholesterol more than a pla…

This study tests a drug called Sac-TMT, given directly into the bladder, for people with a type of bladder cancer that hasn't spread into the muscle. The main goals are to check the drug's safety and find the best dose. About 32 people with recurrent low-grade tumors will take pa…

This study compares a new drug, nemtabrutinib, with two standard treatments (ibrutinib or acalabrutinib) in people with untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. About 1,200 participants will be randomly assigned to receive either nemtabrutinib or the …

This early-stage study tests a new targeted drug called MK-8294 in about 67 people with advanced solid tumors that have spread. The main goal is to check the drug's safety and find the highest dose people can tolerate. Researchers will also watch for any tumor shrinkage, but this…

This study is for people already taking belzutifan in another trial for advanced solid tumors or von Hippel-Lindau (VHL) disease. Belzutifan blocks a protein that helps tumors grow. The goal is to see how long people live and track any side effects over time. About 450 adults wil…

This study tests a new immunotherapy, MK-1045, against a standard treatment (blinatumomab) in people whose B-cell acute lymphoblastic leukemia has returned or not responded to prior therapy. About 340 adults with CD19-positive disease will be enrolled. The main goals are to see i…

This study tests a new drug called tulisokibart in 1,200 people with moderate-to-severe Crohn's disease. The goal is to see if it can reduce symptoms and heal the gut better than a placebo. Participants must have tried other treatments without success. The study lasts up to 52 we…

This study tests a medicine called sotatercept in 42 children aged 1 to 17 who have pulmonary arterial hypertension (PAH), a serious lung condition that makes it hard to pump blood. The goal is to see if the drug is safe and how the body processes it over 24 weeks. All children w…

This study tests whether adding a new drug (patritumab deruxtecan) to standard immunotherapy (pembrolizumab) with or without chemotherapy can better control advanced non-small cell lung cancer. About 90 people with untreated stage IV lung cancer will participate. The goal is to s…

This study tests whether adding a targeted therapy (Sac-TMT) to standard chemotherapy and immunotherapy before surgery helps eliminate more cancer in high-risk, early-stage triple-negative or hormone-receptor-low/HER2-negative breast cancer. About 2,400 participants will receive …

This study tests whether adding a personalized mRNA vaccine (V940) to standard immunotherapy (pembrolizumab) can stop advanced melanoma from growing or spreading. About 160 people with stage III or IV melanoma that cannot be removed by surgery will receive either the vaccine plus…

This study tests a new drug, sacituzumab tirumotecan, against standard chemotherapy for people with advanced bladder cancer that has gotten worse after prior treatments. About 590 participants will be randomly assigned to receive either the new drug or a chemotherapy chosen by th…

This study follows about 3,500 adults with solid tumors or blood cancers who are already taking or have taken pembrolizumab in earlier trials. Researchers will track long-term safety and how well the drug controls the disease over time. Participants may continue treatment or be m…

This study is for people with stage IV non-small cell lung cancer who have not had any prior treatment. It tests whether adding new experimental drugs to the standard immunotherapy (pembrolizumab) with or without chemotherapy can shrink tumors or control the disease better. About…

This study tests a new drug called raludotatug deruxtecan (R-DXd) for people with a fast-growing type of ovarian cancer that has returned after standard chemotherapy. R-DXd is an antibody drug conjugate that targets and destroys cancer cells. The study will check safety and how w…

This study tests a new medicine called MK-5684 that blocks the body from making steroid hormones, which some cancers need to grow. About 250 people with breast, ovarian, or endometrial cancer will receive either MK-5684 or standard treatment. Researchers want to see if MK-5684 he…

This early-phase study tests a new drug called MK-1084 (calderasib) in people with advanced solid tumors that have a specific genetic change called KRAS G12C. The drug is given alone or with other treatments. The main goals are to check safety, how the body processes the drug, an…

This study tests whether adding the drug MK-2870 to standard immunotherapy (pembrolizumab) after surgery can better prevent lung cancer from coming back. It is for people with stage II to IIIB non-small cell lung cancer whose tumor did not fully disappear after chemotherapy and i…

This study tests whether adding new investigational drugs to standard chemotherapy and immunotherapy (pembrolizumab) can safely treat advanced stomach, gastroesophageal junction, or esophageal cancer that has not spread to other organs. About 160 adults whose cancer is HER2-negat…

This study is for people with extensive-stage small cell lung cancer whose disease got worse after initial treatment with immunotherapy and chemotherapy. Researchers are testing new drugs, either alone or combined with pembrolizumab, to see if they can shrink tumors or slow the c…

This study is for people with certain blood cancers (like essential thrombocythemia or myelofibrosis) who have already been taking the drug bomedemstat and are doing well on it. The goal is to collect more information on the drug's long-term safety and how well it continues to wo…

This early-stage study tests a new medicine called MK-1403 in people with type 2 diabetes. The main goals are to check if it is safe and well-tolerated, and to see how the body processes it. Researchers will also measure if it lowers a marker of inflammation (hsCRP) in the blood.…

This study tests a new drug called opevesostat (plus hormone replacement therapy) against two standard drugs (abiraterone or enzalutamide) in men with metastatic castration-resistant prostate cancer that got worse after one prior hormone treatment. About 1,314 participants will b…

This early-stage study tests a new experimental drug, MK-4646, in 28 people with HIV-1 who have never taken HIV medication. The main goals are to see if the drug is safe and tolerable, and how much it can lower the amount of virus in the blood. Participants will take the drug alo…

This study tests the safety and drug levels of doravirine, an HIV medicine, in children aged 4 weeks to under 12 years who weigh less than 45 kg. Participants either have never taken HIV treatment or have their virus under control with other meds. The goal is to find the right do…

This study tests whether adding the experimental drug zilovertamab vedotin to standard chemotherapy helps people with diffuse large B-cell lymphoma that has come back or not responded to prior treatment. About 290 adults will be randomly assigned to receive either the new combina…

This study tests a new drug called MK-3120 in people with advanced solid tumors that have spread and cannot be removed by surgery. The main goal is to see if the drug is safe and tolerable. About 270 adults who have tried all other available treatments will take part.

This study tests whether a new drug, zilovertamab vedotin, combined with standard chemotherapy (R-CHP) works better than another approved drug combo (polatuzumab vedotin + R-CHP) for people with a specific type of fast-growing blood cancer called GCB diffuse large B-cell lymphoma…

This study tests whether a new targeted pill (MK-1084) combined with an immunotherapy (pembrolizumab) can help people with a specific KRAS-mutated advanced lung cancer live longer without their cancer growing, compared to standard chemo plus immunotherapy. About 675 adults with n…

This study tests whether the antiviral pill molnupiravir can prevent severe illness from COVID-19 in adults who are at high risk due to other health conditions. About 3,000 participants will receive either the drug or a placebo and be monitored for 29 days. The goal is to see if …

This study is for people with advanced bladder cancer that has stopped responding to standard immunotherapy. It tests new drug combinations, with or without the drug pembrolizumab, to see if they can shrink tumors or slow the disease. About 48 adults will take part, and the main …

This study tests new antibody-drug conjugates (ADCs) in people with advanced squamous non-small cell lung cancer that did not respond to standard immunotherapy or chemotherapy. ADCs are like guided missiles that deliver a powerful drug directly to cancer cells. The study will com…

This study tests a drug called I-DXd in people with advanced esophageal cancer that has not responded to prior treatments. I-DXd is designed to attach to cancer cells and deliver a powerful treatment directly to them. The main goal is to see how many participants have their tumor…

This study tests a new drug (MK-2870) alone or with another drug (pembrolizumab) against standard treatments for people with a common type of advanced breast cancer (HR+/HER2-). About 1,200 participants whose cancer has spread or cannot be removed will be randomly assigned to one…

This study tests whether adding a new medicine called enlicitide to a standard statin (rosuvastatin) lowers bad cholesterol more than a placebo plus the statin. About 975 adults with high cholesterol will take either the combo or a dummy pill for 8 weeks. The main goal is to see …

This study looks at the long-term safety of the medicine sotatercept when added to standard treatments for pulmonary arterial hypertension (PAH), a condition where lung blood vessels narrow, making breathing and activity difficult. About 815 adults who completed earlier sotaterce…

This study tests whether adding zanzalintinib to belzutifan helps people with advanced kidney cancer live longer and keep the cancer from growing. About 758 adults whose cancer worsened after standard treatments will receive either the drug combo or belzutifan alone. The goal is …

This study tests whether adding a new drug (patritumab deruxtecan) to standard chemotherapy and immunotherapy before surgery can eliminate more cancer cells in people with high-risk early-stage triple-negative or hormone-receptor-low breast cancer. About 372 participants will be …

This study is for people with advanced nonsquamous non-small cell lung cancer that has spread and no longer responds to standard immunotherapy or chemotherapy. Researchers are testing two antibody-drug conjugates (ADCs) — targeted drugs that deliver treatment directly to cancer c…

This study tests whether a new monthly pill (MK-8527) is better than the standard daily pill at preventing HIV infection in women. About 4,580 HIV-negative women who are sexually active will take either the monthly pill or a daily PrEP pill for comparison. Researchers will track …

This study tests whether a new pill taken once a month (MK-8527) can prevent HIV-1 infection as well as the standard daily PrEP pill. About 4,390 adults at risk for HIV will participate. The goal is to find a more convenient prevention option that people can take less often.

This study tests the drug letermovir to prevent cytomegalovirus (CMV) infection in children and teens who have had a kidney transplant and weigh less than 40 kg. About 40 participants will receive the drug to see how it moves through the body and if it is safe. The goal is to fin…

This early-stage study is testing a new weight loss medicine called MK-4082, taken as a pill rather than an injection. Researchers want to see if it is safe and how the body handles different doses. The study involves 120 healthy adults with a body mass index (BMI) between 25 and…

This study tests whether the sleep medication suvorexant can help people with opioid use disorder who also have insomnia fall asleep and stay asleep longer. About 300 adults on stable medication for opioid use disorder will receive either suvorexant or a placebo for 8 weeks. Rese…

This study tests whether tulisokibart can reduce symptoms like joint pain and swelling in adults with active psoriatic arthritis. About 140 participants will receive either the study drug or a placebo. Researchers will measure improvement at 16 weeks using standard arthritis resp…

This early-stage study tests a new medicine called MK-1045 in 21 people with lupus or rheumatoid arthritis. The main goal is to check if the drug is safe and tolerable at different doses. This is not a cure; it aims to understand how the drug works in the body and its side effect…

This study tests a new experimental HIV medicine, MK-4646, in 16 healthy adults to see how it interacts with two standard HIV treatments: BIC/FTC/TAF and dolutegravir. Researchers will measure drug levels in the blood and check for side effects. The goal is to ensure safety befor…

This study looks at how the drug itraconazole changes the amount of MK-2828 in the body, and how MK-2828 changes the amount of midazolam. It involves 28 healthy adults and is in Phase 1. The goal is to understand drug interactions, not to treat any disease.

This study looks at how the drug nemtabrutinib is processed in the body of people with moderate liver impairment compared to healthy people. About 32 adults will take a single dose of the drug, and researchers will measure drug levels and safety. The goal is to understand if live…

This study looks at how the drug MK-1084 (calderasib) moves through the body in people with liver problems compared to healthy people. About 58 adults will take a single dose, and researchers will measure drug levels and check for side effects. The goal is to understand if liver …

This study enrolls 330 healthy adults to see if two different autoinjectors deliver the same amount of the drug tulisokibart into the body. Researchers will measure drug levels in the blood and watch for any side effects. The goal is to make sure both devices work the same way be…

This study looks at how a single dose of ulonivirine changes the way the body processes atorvastatin and metformin. It involves 12 healthy adults and is purely for gathering information, not for treating any disease. The results will help guide future use of ulonivirine with thes…

This study tests a new prostate cancer drug called opevesostat in 14 healthy men to see how it behaves in the body when taken with or without another drug, itraconazole. The goal is to understand how the body processes opevesostat, which may help guide future dosing for prostate …

This early-stage study in 39 healthy adults checks if a new heart failure medicine called MK-2828 affects how the body handles two common drugs: rosuvastatin and furosemide. The goal is to gather safety and interaction data, not to treat any disease. Participants must be in good …

This study looks at how the drug MK-2828 behaves in the bodies of people with different levels of kidney function, including those on dialysis. About 24 adults will receive one or two doses, and researchers will track the drug levels in their blood over time. The goal is to see i…